Champions Oncology, Inc. – NASDAQ:CSBR

Champions Oncology stock price today

$7.62
-0.72
-8.74%
Financial Health
0
1
2
3
4
5
6
7
8
9

Champions Oncology stock price monthly change

+65.02%
month

Champions Oncology stock price quarterly change

+65.02%
quarter

Champions Oncology stock price yearly change

+57.70%
year

Champions Oncology key metrics

Market Cap
105.30M
Enterprise value
60.97M
P/E
-19.59
EV/Sales
1.13
EV/EBITDA
-72.50
Price/Sales
1.18
Price/Book
9.02
PEG ratio
-0.58
EPS
-0.58
Revenue
50.74M
EBITDA
-4.40M
Income
-7.87M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
-5.81%
Oper. margin
-5.67%
Gross margin
47.06%
EBIT margin
-5.67%
EBITDA margin
-8.69%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Champions Oncology stock price history

Champions Oncology stock forecast

Champions Oncology financial statements

Champions Oncology, Inc. (NASDAQ:CSBR): Profit margin
Apr 2022 12.87M -344K -2.67%
Jan 2023 12.77M -2.43M -19.09%
Apr 2023 13.07M -2.56M -19.59%
Jan 2024 12.01M -2.53M -21.05%
Champions Oncology, Inc. (NASDAQ:CSBR): Analyst Estimates
2026 59.31M 677.07K 1.14%
2027 66.72M 0
  • Analysts Price target

  • Financials & Ratios estimates

Champions Oncology, Inc. (NASDAQ:CSBR): Earnings per share (EPS)
2024-07-18 -0.16 -0.01
2024-09-11 0.01941 0.11
Champions Oncology, Inc. (NASDAQ:CSBR): Debt to assets
Oct 2022 36364000 27.19M 74.78%
Jan 2023 36151000 29.08M 80.46%
Apr 2023 34311000 29.67M 86.49%
Jan 2024 26787000 28.84M 107.68%
Champions Oncology, Inc. (NASDAQ:CSBR): Cash Flow
Apr 2022 796K -506K 16K
Jan 2023 1.57M -754K 0
Apr 2023 -709K -760K -75K
Jan 2024 -919K -126K 0

Champions Oncology alternative data

Champions Oncology, Inc. (NASDAQ:CSBR): Employee count
Aug 2023 230
Sep 2023 230
Oct 2023 230
Nov 2023 230
Dec 2023 230
Jan 2024 230
Feb 2024 230
Mar 2024 230
Apr 2024 230
May 2024 230
Jun 2024 230
Jul 2024 230

Champions Oncology other data

10.08% -34.30%
of CSBR is owned by hedge funds
1.36M -4.63M
shares is hold by hedge funds

Champions Oncology, Inc. (NASDAQ:CSBR): Insider trades (number of shares)
Period Buy Sel
Mar 2023 12382 0
Sep 2023 22830 0
Oct 2023 17130 0
Dec 2023 9600 0
Jan 2024 15444 0
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
MENDELSON DANIEL NEWMAN director
Common Stock 1,000 $6.5 $6,500
Purchase
MENDELSON DANIEL NEWMAN director
Common Stock 2,000 $6.27 $12,540
Purchase
MENDELSON DANIEL NEWMAN director
Common Stock 2,944 $6.31 $18,577
Purchase
MENDELSON DANIEL NEWMAN director
Common Stock 3,000 $6.25 $18,750
Purchase
MENDELSON DANIEL NEWMAN director
Common Stock 1,000 $6.15 $6,150
Purchase
MENDELSON DANIEL NEWMAN director
Common Stock 2,000 $6.09 $12,180
Purchase
MENDELSON DANIEL NEWMAN director
Common Stock 3,000 $6.12 $18,360
Purchase
MENDELSON DANIEL NEWMAN director
Common Stock 500 $5.83 $2,915
Purchase
MENDELSON DANIEL NEWMAN director
Common Stock 2,500 $4.92 $12,300
Purchase
MENDELSON DANIEL NEWMAN director
Common Stock 2,100 $4.82 $10,122
Insider Compensation
Dr. Ronnie Morris M.D. (1966) Pres, Chief Executive Officer & Director $775,000
Mr. David Barry Miller M.B.A. (1969) Chief Financial Officer
$285,000
Friday, 27 December 2024
seekingalpha.com
Wednesday, 11 December 2024
seekingalpha.com
accesswire.com
Thursday, 5 December 2024
accesswire.com
Wednesday, 16 October 2024
accesswire.com
Wednesday, 11 September 2024
seekingalpha.com
accesswire.com
Monday, 9 September 2024
accesswire.com
Thursday, 18 July 2024
accesswire.com
Thursday, 11 July 2024
accesswire.com
Tuesday, 4 June 2024
accesswire.com
Tuesday, 12 March 2024
seekingalpha.com
accesswire.com
Thursday, 7 March 2024
accesswire.com
Wednesday, 6 March 2024
Accesswire
Tuesday, 12 December 2023
Seeking Alpha
Monday, 4 December 2023
Accesswire
Thursday, 20 July 2023
Accesswire
Wednesday, 15 March 2023
Zacks Investment Research
Monday, 13 March 2023
Accesswire
Sunday, 29 January 2023
Seeking Alpha
Tuesday, 13 December 2022
Seeking Alpha
Friday, 9 December 2022
Accesswire
Friday, 9 September 2022
Seeking Alpha
Thursday, 8 September 2022
Zacks Investment Research
Tuesday, 29 March 2022
Zacks Investment Research
Wednesday, 16 March 2022
Seeking Alpha
Friday, 11 March 2022
Accesswire
Monday, 13 December 2021
Seeking Alpha
Monday, 6 December 2021
Accesswire
  • What's the price of Champions Oncology stock today?

    One share of Champions Oncology stock can currently be purchased for approximately $7.62.

  • When is Champions Oncology's next earnings date?

    Unfortunately, Champions Oncology's (CSBR) next earnings date is currently unknown.

  • Does Champions Oncology pay dividends?

    No, Champions Oncology does not pay dividends.

  • How much money does Champions Oncology make?

    Champions Oncology has a market capitalization of 105.30M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 6.9% to 50.16M US dollars. Champions Oncology made a loss 7.28M US dollars in net income (profit) last year or $0.11 on an earnings per share basis.

  • What is Champions Oncology's stock symbol?

    Champions Oncology, Inc. is traded on the NASDAQ under the ticker symbol "CSBR".

  • What is Champions Oncology's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Champions Oncology?

    Shares of Champions Oncology can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Champions Oncology's key executives?

    Champions Oncology's management team includes the following people:

    • Dr. Ronnie Morris M.D. Pres, Chief Executive Officer & Director(age: 59, pay: $775,000)
    • Mr. David Barry Miller M.B.A. Chief Financial Officer(age: 56, pay: $285,000)
  • How many employees does Champions Oncology have?

    As Jul 2024, Champions Oncology employs 230 workers.

  • When Champions Oncology went public?

    Champions Oncology, Inc. is publicly traded company for more then 18 years since IPO on 2 Feb 2007.

  • What is Champions Oncology's official website?

    The official website for Champions Oncology is championsoncology.com.

  • Where are Champions Oncology's headquarters?

    Champions Oncology is headquartered at One University Plaza, Hackensack, NJ.

  • How can i contact Champions Oncology?

    Champions Oncology's mailing address is One University Plaza, Hackensack, NJ and company can be reached via phone at +20 18088400.

Champions Oncology company profile:

Champions Oncology, Inc.

championsoncology.com
Exchange:

NASDAQ

Full time employees:

210

Industry:

Biotechnology

Sector:

Healthcare

Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. The company provides Lumin Bioinformatics, a software platform and data tool that contains comprehensive information derived from research services and clinical studies, and sold on an annual subscriptions basis. The company markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.

One University Plaza
Hackensack, NJ 07601

CIK: 0000771856
ISIN: US15870P3073
CUSIP: 15870P307